<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02248051</url>
  </required_header>
  <id_info>
    <org_study_id>CXA-10-002</org_study_id>
    <nct_id>NCT02248051</nct_id>
  </id_info>
  <brief_title>Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury</brief_title>
  <official_title>An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complexa, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to demonstrate the safety, tolerability and&#xD;
      pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient&#xD;
      population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition,&#xD;
      associated pharmacodynamic (PD) effects of CXA-10 will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, open-label study, single-dose study with CXA-10 in subjects with&#xD;
      CKI. At total of 12 subjects will be enrolled into two equal groups according to their&#xD;
      baseline estimated glomerular filtration rate (eGFR: 15 - 39 or 40 - 59 mL/min/1.73m2). All&#xD;
      subjects will receive a single dose infusion of CXA-10 emulsion. Since this is the first&#xD;
      administration of CXA-10 to a non-healthy volunteer population, a conservative approach is&#xD;
      being taken to ensure safety. Thus, the first 2 subjects from each group will be dosed at one&#xD;
      dose level below the highest safe dose level administered in the FIH study. If this dose is&#xD;
      found to be safe in this specific subject population, the remainder of the 4 subjects in each&#xD;
      group will receive the highest safe dose from the FIH study; otherwise, the remainder will&#xD;
      receive the initial dose. The doses administered in this study will not exceed the highest&#xD;
      exposures achieved in the FIH study, and doses may need to be adjusted to lower levels, based&#xD;
      on further evaluation of current pharmacokinetic data, to ensure the appropriate the exposure&#xD;
      level. Safety, PK and PD assessments will be conducted over approximately 18 days following&#xD;
      each dosing session. There will be a follow-up visit approximately 1 week after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Serious and Non-Serious Adverse Events</measure>
    <time_frame>First day of dosing through 30 days</time_frame>
    <description>Safety assessments will be performed prior to, during, and after dosing including a visit on Day 18</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Kidney Injury (Nontraumatic)</condition>
  <arm_group>
    <arm_group_label>CXA-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXA-10</intervention_name>
    <description>CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.</description>
    <arm_group_label>CXA-10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects of non-child bearing potential 18 to 70 years of age&#xD;
             (inclusive).&#xD;
&#xD;
          2. Moderate to severe CKI (equivalent to National Kidney Foundation Kidney Disease&#xD;
             Outcomes Quality Initiative [NKF KDOQI] Stage 3 or 4, not receiving dialysis) as&#xD;
             determined by estimated glomerular filtration rate (eGFR) greater than or equal to 15&#xD;
             and less than 60 mL/min/1.73 m2 (according to the creatinine-cystatin C equation)&#xD;
             within less than or equal to 3 months prior to the screening visit. Cause of the CKI&#xD;
             should be recorded where possible.&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive)&#xD;
&#xD;
          4. Subjects must have resting heart rates (HR) greater than or equal to 50 beats per&#xD;
             minute at baseline&#xD;
&#xD;
          5. QTcF interval (Fredericia's correction factor) of the baseline ECG must be less than&#xD;
             or equal to 450 msec for males and less than or equal to 470 msec for females at&#xD;
             screening and predose. Subjects with any other clinically relevant ECG parameter&#xD;
             abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG&#xD;
             abnormality will be excluded from the study. Subjects with a history of congenital&#xD;
             long QT syndrome or short QT syndrome in the subject or in the subject's family will&#xD;
             be excluded from the study.&#xD;
&#xD;
          6. Adequate bilateral venous access to allow for dose infusions and blood sampling&#xD;
&#xD;
          7. Ability to comprehend and comply with procedures&#xD;
&#xD;
          8. Agree to commit to participate in the current protocol&#xD;
&#xD;
          9. Provide written informed consent prior to any study procedure being performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant or lactating or who are trying to conceive&#xD;
&#xD;
          2. Female subjects with a positive serum β-human chorionic gonadotropin (β-hCG) test at&#xD;
             screening or Day -1 for any dosing day&#xD;
&#xD;
          3. History of renal transplantation&#xD;
&#xD;
          4. History of acute dialysis or acute kidney injury within 12 wks prior to screening and&#xD;
             dosing&#xD;
&#xD;
          5. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 3.0X upper&#xD;
             limit of normal (ULN), gamma-glutamyl transferase (GGT) greater than 3X ULN, and total&#xD;
             bilirubin greater than 2X ULN. If all liver function tests (LFTs) are within normal&#xD;
             limits (WNL) and total bilirubin is elevated, examination of direct and indirect&#xD;
             bilirubin may be conducted. Subjects with indirect total bilirubin up to 3X ULN are&#xD;
             presumed to have Gilbert's syndrome and may be enrolled if all other LFTs are WNL.&#xD;
&#xD;
          6. Presence of signs and symptoms of uremia&#xD;
&#xD;
          7. Past history of pancreatitis&#xD;
&#xD;
          8. History of documented hypersensitivity reaction to eggs or egg products (as the&#xD;
             vehicle contains egg phospholipids)&#xD;
&#xD;
          9. History of documented hypersensitivity reaction to soy or soy products (as vehicle&#xD;
             contains soy bean oil)&#xD;
&#xD;
         10. Uncontrolled diabetes with HbA1c &gt; 9 percent or subjects with frequent hypoglycemic&#xD;
             attacks&#xD;
&#xD;
         11. Active cardiovascular disease within 12 weeks of dosing, including unstable angina,&#xD;
             myocardial infarction, coronary artery bypass or percutaneous transluminal&#xD;
             angioplasty/stent, cerebrovascular accident including transient ischemic attack, any&#xD;
             history of syncope, dizziness, cardiac arrhythmias, cardiac arrest, pacemakers,&#xD;
             cardioversion, and clinical diagnosis of severe obstructive valvular heart disease or&#xD;
             severe hypertrophic cardiomyopathy&#xD;
&#xD;
         12. Current diagnosis of Class 3 or 4 New York Heart Association (NYHA) congestive heart&#xD;
             failure.&#xD;
&#xD;
         13. Uncontrolled hypertension with sitting blood pressure greater than 160 mmHg systolic&#xD;
             and or greater than 100 mmHg diastolic after 5 minutes rest (feet on floor, arm held&#xD;
             at level of heart) at the screening visit&#xD;
&#xD;
         14. Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes&#xD;
             rest (as above) at the screening visit&#xD;
&#xD;
         15. Any abnormalities on 12-lead ECG, as deemed by the investigator and/or medical&#xD;
             monitor, at screening&#xD;
&#xD;
         16. Any clinically significant murmurs evident on auscultation of the heart (including&#xD;
             evidence of mitral valve prolapse)&#xD;
&#xD;
         17. History of smoking or use of nicotine-containing products in excess of approximately a&#xD;
             pack per day (estimated at 20 cigarettes per day) or equivalent within the past 2&#xD;
             weeks&#xD;
&#xD;
         18. History of drug abuse or dependence within 6 months of the study&#xD;
&#xD;
         19. History of regular alcohol consumption within 6 months of the study, defined as an&#xD;
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is&#xD;
             equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125&#xD;
             mL) of wine or 1 measure (25 mL) of spirits.&#xD;
&#xD;
         20. A positive drug screen for drugs of abuse, including alcohol at the screening visit or&#xD;
             at entry to the clinic&#xD;
&#xD;
         21. Treatment with any investigational drug within 30 days or 5 half-lives prior to the&#xD;
             beginning of the screening period (this includes investigational formulations of&#xD;
             marketed products, inhaled and topical drugs)&#xD;
&#xD;
         22. Blood collection of greater than 500 mL within 56 days prior to screening&#xD;
&#xD;
         23. Seropositive for human immunodeficiency virus (HIV) at screening&#xD;
&#xD;
         24. Positive for Hepatitis B virus surface antigen (HBsAg) or positive Hepatitis C virus&#xD;
             antibody (HCV Ab) at screening&#xD;
&#xD;
         25. Any other condition and/or situation that causes the Investigator to deem a subject&#xD;
             unsuitable for the study (e.g., due to expected study medication non compliance,&#xD;
             inability to medically tolerate the study procedures, or a subject's unwillingness to&#xD;
             comply with study related procedures)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasper Clinical Research &amp; Development, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CXA-10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02248051
org study id: CXA-10-002
nct id: NCT02248051
lead sponsor: 
has dmc: No
The main purpose of this trial is to demonstrate the safety, tolerability and
      pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient
      population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition,
      associated pharmacodynamic (PD) effects of CXA-10 will be investigated.
This will be a multi-center, open-label study, single-dose study with CXA-10 in subjects with
      CKI. At total of 12 subjects will be enrolled into two equal groups according to their
      baseline estimated glomerular filtration rate (eGFR: 15 - 39 or 40 - 59 mL/min/1.73m2). All
      subjects will receive a single dose infusion of CXA-10 emulsion. Since this is the first
      administration of CXA-10 to a non-healthy volunteer population, a conservative approach is
      being taken to ensure safety. Thus, the first 2 subjects from each group will be dosed at one
      dose level below the highest safe dose level administered in the FIH study. If this dose is
      found to be safe in this specific subject population, the remainder of the 4 subjects in each
      group will receive the highest safe dose from the FIH study; otherwise, the remainder will
      receive the initial dose. The doses administered in this study will not exceed the highest
      exposures achieved in the FIH study, and doses may need to be adjusted to lower levels, based
      on further evaluation of current pharmacokinetic data, to ensure the appropriate the exposure
      level. Safety, PK and PD assessments will be conducted over approximately 18 days following
      each dosing session. There will be a follow-up visit approximately 1 week after dosing.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of subjects with Serious and Non-Serious Adverse Events
time frame: First day of dosing through 30 days
description: Safety assessments will be performed prior to, during, and after dosing including a visit on Day 18
arm group label: CXA-10
arm group type: Experimental
intervention type: Drug
intervention name: CXA-10
description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
arm group label: CXA-10
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Acute Kidney Injury
mesh term: Wounds and Injuries
mesh term: CXA-10
sharing ipd: No